Ranbaxy Outperforms Behind Generic Valtrex, But FDA Corrective Action Looms
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's Ranbaxy Laboratories, now a subsidiary of Japanese Daiichi Sankyo, has posted better than expected first quarter results and has many positive developments to look forward to, but analysts remain cautious about potential U.S. FDA action and turnaround time of generic opportunities in Japan
You may also be interested in...
Daiichi Sankyo Rolls Out Generics In Japan While Ranbaxy Products Still On Hold In U.S.
TOKYO - Daiichi Sankyo has initiated operations for its Ranbaxy-supported generics subsidiary in Japan - Daiichi Sanyko Espha - a positive step for the company's established products plans as it awaits news on U.S. FDA action on Ranbaxy
Daiichi Sankyo Rolls Out Generics In Japan While Ranbaxy Products Still On Hold In U.S.
TOKYO - Daiichi Sankyo has initiated operations for its Ranbaxy-supported generics subsidiary in Japan - Daiichi Sanyko Espha - a positive step for the company's established products plans as it awaits news on U.S. FDA action on Ranbaxy
Ranbaxy Loses Tamsulosin Launch Opportunity To Impax; Analysts Raise Doubts About Nexium, Lipitor
MUMBAI - It's been a tricky and awkward situation for Ranbaxy since it admitted at the last minute to losing a big opportunity of launching the first generic version of prostate enlargement drug Flomax (tamsulosin) in the United States. On March 2, Impax launched the generic variant of the nearly $2 billion blockbuster drug as part of an October 2009 patent settlement inked with Boehringer Ingelheim